Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil versus alfentanil combined with propofol and low-dose midazolam for colonoscopy sedation
ACTRN12618001451291Phase 4Completed
- Sponsor
- Necmettin Erbakan University Meram School of Medicine
- Start
- Dec 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remifentanil, alfentanil, propofol and midazolam in None (2 arms), sponsored by Necmettin Erbakan University Meram School of Medicine. Primary endpoints: Awake time, Recovery time and 1 more. Started Dec 2017; status: completed.
02
Drugs
remifentanilalfentanilpropofolmidazolam
Beyond the preview
Go deeper on ACTRN12618001451291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001451291.